Document Detail


Pharmacological treatment of acute and chronic hyperuricemia in kidney diseased patients.
MedLine Citation:
PMID:  15604614     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Several trials argued the possibility that hyperuricemia may have a direct effect on cardiovascular and renal disease. It has been shown that an elevated serum uric acid concentration is a predictor of cardiovascular events such as myocardial infarction. It also predicts the development of hypertension and in hypertensive patients, hyperuricemia is associated with increased cardiovascular morbidity and mortality. Hyperuricemia is a complication often seen in patients with chronic and acute renal disease. The relationship between serum uric acid level and the appearance or progression of renal dysfunction has been debated in the last years. During chemotherapy for hematological malignancies or more rarely for solid tumors, acute renal failure, secondary to a sudden marked increase in uric acid, is not such a rare complication. The therapeutic intervention includes hyper hydration, urinary alkalinization, and the use of uric acid decreasing agents such as allopurinol and rasburicase, a recent recombinant-urate oxidase. In our personal experience, patients with acute renal failure due to hyperuricemia, showed a better renal prognosis with rasburicase than allopurinol. Chronic hyperuricemia is also associated with chronic tubulo-interstitial disease with glomerular sclerosis, and renal dysfunction. Experimental trials showed that uric acid can affect kidneys through different mechanisms at glomerular, tubulo-interstitial and vascular level. Although allopurinol is often the drug of choice, caution must be used to avoid serious side effects. New therapeutic options, for treating hyperuricemia are needed in patients with renal dysfunction for slowing the progression to end stage kidney disease.
Authors:
Guido Bellinghieri; Domenico Santoro; Vincenzo Savica
Related Documents :
16647624 - Urotensin ii and biomarkers of endothelial activation and atherosclerosis in end-stage ...
12826134 - Diabetes mellitus in transplantation: 2002 consensus guidelines.
17893004 - Low plasma levels of adiponectin are associated with low risk for future cardiovascular...
11738274 - Renal function: the cinderella of cardiovascular risk profile.
11443574 - Right hepatic lobe donation for living donor liver transplantation: impact on donor qua...
678754 - An evaluation of the use of 99tcm-dimercaptosuccinic acid (dmsa) as a static renal imag...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Contributions to nephrology     Volume:  147     ISSN:  0302-5144     ISO Abbreviation:  Contrib Nephrol     Publication Date:  2005  
Date Detail:
Created Date:  2004-12-17     Completed Date:  2005-01-26     Revised Date:  2007-11-20    
Medline Journal Info:
Nlm Unique ID:  7513582     Medline TA:  Contrib Nephrol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  149-60     Citation Subset:  IM    
Affiliation:
Department of Medicine and Pharmacology, Division of Nephrology, University of Messina, Messina, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Chronic Disease
Humans
Hyperuricemia / drug therapy*,  etiology
Kidney Diseases / drug therapy*
Tumor Lysis Syndrome / complications

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Uric acid elimination in the urine. Pathophysiological implications.
Next Document:  Pharmacological treatment of acute renal failure in intensive care unit patients.